Stockscreener 앱 받기
6.695
1.69%
-0.115
시간 외 거래:
6.70
0.005
+0.07%
전일 마감가:
$6.81
열려 있는:
$6.71
하루 거래량:
13,353
Relative Volume:
0.36
시가총액:
$49.03M
수익:
$7.00M
순이익/손실:
$-61.71M
주가수익비율:
-0.7929
EPS:
-8.4433
순현금흐름:
$-56.66M
1주 성능:
-6.75%
1개월 성능:
-0.07%
6개월 성능:
+78.06%
1년 성능:
+14.84%
1일 변동 폭
$6.62
$6.78
1주일 범위
$6.62
$7.25
52주 변동 폭
$3.5334
$7.45
Kezar Life Sciences Inc Stock (KZR) Company Profile
명칭
Kezar Life Sciences Inc
전화
650-822-5600
주소
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
6.695 | 49.87M | 7.00M | -61.71M | -56.66M | -8.4433 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-10-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-08-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Wells Fargo | Outperform |
| 2018-07-16 | 개시 | William Blair | Outperform |
모두보기
Kezar Life Sciences Inc 주식(KZR)의 최신 뉴스
Enodia jumps ahead in Sec61 targeting, adds Kezar’s program - BioWorld MedTech
Spring break for biotech deals? - BioCentury
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Deal Watch: Enodia Turns To Kezar To Advance Sec61 Programs - Citeline News & Insights
Enodia acquires Sec61 assets from Kezar Life Sciences - bioworld.com
Enodia acquires Kezar’s Sec61 program assets for $127M potential By Investing.com - Investing.com Canada
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences - PharmiWeb.com
Kezar Divests Sec61 Program to Refocus on Core Pipeline - TipRanks
Enodia Therapeutics strengthens Sec61 portfolio through acquisition of preclinical assets from Kezar Life Sciences - marketscreener.com
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition Of Preclinical Assets From Kezar Life Sciences - TradingView
Kezar Life Sciences Sells Sec61 Program to Enodia Therapeutics for Upfront Cash, Up to $127M Milestones - TradingView
Kezar Life Sciences (NASDAQ: KZR) sells Sec61 assets to Enodia with $127M milestones - Stock Titan
Kezar Life Sciences (KZR) Price Target Decreased by 52.00% to 6.12 - MSN
Entry Recap: Is Kezar Life Sciences Inc a play on infrastructure spendingBear Alert & Verified Chart Pattern Signals - baoquankhu1.vn
How cyclical is Kezar Life Sciences Inc. (2KZ0) stock compared to rivalsMarket Sentiment Summary & Reliable Price Breakout Signals - Naître et grandir
Layoff Watch: Why is Kezar Life Sciences Inc stock going upTake Profit & Safe Capital Growth Tips - baoquankhu1.vn
Downgrade Watch: What are Kezar Life Sciences Incs recent SEC filings showingTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
KZR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quarterly Trades: Will CRISPR Therapeutics AG benefit from government policyJuly 2025 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
Aug Analyst Calls: Why is Kezar Life Sciences Inc stock going upInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Activity Recap: Is Kezar Life Sciences Inc undervalued by DCF analysisTrade Risk Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Volume: Is Kezar Life Sciences Inc undervalued by DCF analysisBull Run & Weekly Return Optimization Plans - baoquankhu1.vn
Buy Signal: Will Stratus Properties Inc benefit from current market trendsPortfolio Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR - Defense World
Will Kezar Life Sciences Inc. stock recover faster than peersProduct Launch & Technical Confirmation Alerts - mfd.ru
Kezar Life Sciences (NASDAQ:KZR) Shares Up 0.3% – What’s Next? - Defense World
How Kezar Life Sciences Inc. stock reacts to Fed rate cuts2025 Short Interest & Daily Profit Maximizing Tips - mfd.ru
Will Kezar Life Sciences Inc. benefit from government policyJuly 2025 EndofMonth & Community Trade Idea Sharing - mfd.ru
Is Kezar Life Sciences Inc. trading at a discountTrade Exit Summary & Long Hold Capital Preservation Plans - mfd.ru
What are Kezar Life Sciences Inc.’s recent SEC filings showingJuly 2025 Fed Impact & Consistent Growth Equity Picks - mfd.ru
Is Kezar Life Sciences Inc. stock positioned for long term growthTrade Exit Summary & Entry Point Strategy Guides - mfd.ru
Published on: 2026-02-09 08:28:44 - baoquankhu1.vn
Chipmakers Recap: What is the next catalyst for Kezar Life Sciences IncJobs Report & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Rating of “Reduce” from Analysts - Defense World
Sectors Review: Will Kezar Life Sciences Inc benefit from government policy2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - baoquankhu1.vn
What is the next catalyst for Kezar Life Sciences Inc.July 2025 News Drivers & Community Consensus Stock Picks - bollywoodhelpline.com
ETF Watch: Will OXLCG benefit from geopolitical trendsJuly 2025 Patterns & Low Drawdown Trading Techniques - baoquankhu1.vn
Growth Review: Should I hold or sell Kezar Life Sciences Inc now2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Layoff Tracker: SonomaBio Downsizes To Extend Runway - BioSpace
Sentiment Watch: Why Kezar Life Sciences Inc stock could rally in 2025Market Activity Summary & Free Technical Confirmation Trade Alerts - Bộ Nội Vụ
Published on: 2026-01-12 22:48:52 - ulpravda.ru
Kezar Life Sciences (KZR) to Discuss Zetomipzomib with FDA - GuruFocus
Kezar Life Sciences: FDA Division Grants Type C Meeting To Discuss Development Of Zetomipzomib - Nasdaq
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - The AI Journal
Why Kezar Life Sciences Inc. stock appeals to dividend seekersMarket Movers & Stepwise Entry/Exit Trade Alerts - Улправда
Can Kezar Life Sciences Inc. stock hit record highs againTrade Performance Summary & Verified Momentum Stock Ideas - Улправда
How Kezar Life Sciences Inc. stock performs in rate cut cyclesMarket Activity Summary & Daily Chart Pattern Signal Reports - Улправда
How Kymera Therapeutics, Inc. stock performs during market volatility - ulpravda.ru
How geopolitical tensions affect Kezar Life Sciences Inc. stockBull Market Opportunities & High Yield Investment Portfolio - Улправда
Discontinued operations of Kezar Life Sciences Inc – GETTEX:2KZ0 - TradingView — Track All Markets
What drives Kezar Life Sciences Inc stock priceGap Up/Gap Down Analysis & Free High Yield Investment Strategies - Early Times
Kezar Life Sciences Inc (KZR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):